Drug profile · INN
clofazimine
LAMPRENE
clofazimine (LAMPRENE) is a dna inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — clofazimine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 2
- Data quality
- 0.84
Quick answer
clofazimine (LAMPRENE) is a dna inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11090326
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
granted -
US 10143702
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
granted -
US 9314477
Compositions comprising rifabutin, clarithromycin, and clofazimine and uses thereof
granted -
US 9198926
Methods and compositions comprising rifabutin, clarithromycin, and clofazimine
granted
Frequently asked questions
What is clofazimine?
clofazimine (LAMPRENE) is a dna inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for clofazimine?
LAMPRENE is a marketed brand name for clofazimine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clofazimine?
clofazimine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.